Saturday 17 October 2026
Export RNAZ’s income statement to Excel — free account
TransCode Therapeutics Inc.
RNAZ Healthcare Biotechnology
In the quarter to June 2026, EPS fell 39.8% and free cash flow fell 28.8%, each against the same quarter a year earlier.
1.70
0.10
−5.56%
Follow RNAZ
TransCode Therapeutics Inc. (RNAZ) P/E ratio
TransCode Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.7× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 1.7×
Ten-year median
0.0×
Current reading's percentile
81
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVM Cel-Sci Corporation compare | n/m |
| RNAZ TransCode Therapeutics Inc. | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NXTC NextCure, Inc. compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | 1.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.1× |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)